Phase 1 Ovarian Cancer Trial, Recruiting NCT07402915 Sponsor: AstraZeneca Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 1 Ovarian Cancer Trial, Recruiting

NCT07402915
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with platinum-resistant, relapsed, high-grade ovarian cancer, primary peritoneal cancer, or fallopian tube cancer, who have had at least one previous treatment containing a platinum-based chemotherapy drug and whose cancer came back or got worse during or within 6 months of finishing that treatment
  • People who have previously received bevacizumab (a targeted therapy) and/or a PARP inhibitor drug as part of their treatment, unless their doctor determined those treatments were not suitable for them
  • People with a general health and activity level rated as 0 or 1 on a standard medical scale, meaning they are either fully active or have only minor restrictions on physically strenuous activity (confirm with trial site)

Who may not be able to join:

  • People who have spinal cord compression, or who have a history of cancer spreading to the membranes surrounding the brain and spinal cord
  • People who still have side effects rated moderate or higher from previous cancer treatments that have not yet resolved
  • People who have a history of non-infectious lung inflammation (a condition affecting the lung tissue) that required steroid tablets, steroid injections, or extra oxygen, or where this type of lung condition cannot be ruled out by scans done at the start of the trial
  • People who have had a serious, uncontrolled illness at any point in the 12 months before the screening stage of the trial
  • People for whom the trial drug itraconazole would be medically unsuitable based on the drug's prescribing information or the treating doctor's assessment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 1-877-240-9479

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Registry
ClinicalTrials.gov
Start date
26 January 2026
Est. completion
15 October 2027

Where this trial is recruiting

🇬🇪 Georgia 🇮🇪 Ireland 🇵🇹 Portugal 🇪🇸 Spain

Primary endpoints

Area under curve from time 0 to time 17 days (AUC0-17days); Maximum plasma drug concentration (Cmax)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov